Member area login

You don't have or don't remember the password!
Click Here

Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da A. Giannace

Is there a role for serum cystatin C as a biomarker of multiple sclerosis?

M.A. Isgrò \| C. Caldarella \| D. Scribano \| L. Colacicco \| A. Giannace \| C. Zuppi \| T. De Michele \|
<p>Multiple sclerosis (MS) is the most common chronic demyelinating disorder of the central nervous system (CNS). No single clinical feature or diagnostic test is sufficient for the diagnosis of MS and the clinical assessment is very difficult, mainly at the early disease stages. Considering MS as a disorder confined to CNS compartment and related to CNS specific pathogenetic pathways, several studies selectively investigated cerebrospinal fluid (CSF) components to detect predictive/prognostic MS markers. Several molecules, such as CSF 14-3-3 protein, tau protein and cystatin C, have been found dysregulated, even though with discordant results. We analyzed serum and CSF cystatin C concentrations of MS patients, comparing them with results obtained from individuals affected by other neurological diseases. We found no statistical differences between groups in CSF cystatin C, cystatin C difference (<span style="font-family:symbol">D</span><sub>CystC</sub> = CSF - serum cystatin C) and ratio (CystC<sub>ratio</sub> = CSF/serum cystatin C). Interestingly, serum cystatin C concentrations of MS patients resulted significantly lower than in control population [0.71 (interquartile range, 0.64-0.84) mg/L vs. 0.80 (0.67-0.93) mg/L, P=0.008], with no gender-related differences. The pathophysiologic explanation of this finding is unclear, although it cannot be excluded that pathologic mechanisms that lead to MS may involve not only the CNS compartment, but also systemic pathogenetic pathways.</p>
Biochimica Clinica ; 38(3) 218-221 Contributi scientifici - Scientific Papers